Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough

被引:16
作者
Schrauder, A. [1 ]
Saleh, S. [2 ]
Sykora, K. W. [3 ]
Hoy, H. [4 ]
Welte, K. [3 ]
Boos, J. [2 ]
Hempel, G. [2 ,5 ]
Grigull, L. [3 ]
机构
[1] Med Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Kiel, Germany
[2] Univ Hosp, Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany
[3] Med Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Hannover, Germany
[4] Med Univ, Dept Biometry & Stat, Hannover, Germany
[5] Univ Munster, Dept Pharmaceut & Med Chem, Munster, Germany
关键词
cyclosporine A; pediatric; pharmacokinetic; monitoring; graft-vs; -host disease; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; POPULATION PHARMACOKINETICS; RISK-FACTORS; BAYESIAN-ESTIMATION; ACUTE-LEUKEMIA; CHILDREN; METHOTREXATE; PROPHYLAXIS; EXPOSURE;
D O I
10.1111/j.1399-3046.2008.00968.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In order to monitor CsA serum levels after SCT, trough levels (C0) are widely used. The aim of this study was to estimate the population and individual PK parameters for patients receiving intravenous CsA after SCT. In 27 pediatric patients after SCT receiving CsA (3 mg/kg/day) every 12 h, a total of 289 CsA concentrations was obtained. To describe the PK parameters of CsA, a two-compartment model with first order elimination was used. Covariate analysis identified body weight, age, and the co-administration with itraconazole and tobramycine as factors influencing the Cl. The statistical comparison of AUC, trough level, and C2 indicates a correlation between AUC and C2, but no correlation between the AUC and C0, r = 0.24 (p = 0.146) vs. r = 0.526 (p = 0.000692), respectively. Our results underscore the fact that CsA trough levels do not reflect the drug exposure in patients receiving intravenous CsA after SCT. By contrast, CsA blood levels measured 2-6 h after CsA infusion showed a better correlation with the AUC. Our data provide new information to optimize the balancing act between GvHD-prophylaxis, graft vs. leukemia effect, and CsA side-effects after SCT.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 28 条
[1]  
BACIGALUPO A, 1991, BLOOD, V77, P1423
[2]   Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients [J].
Bourgoin, H ;
Paintaud, G ;
Büchler, M ;
Lebranchu, Y ;
Autret-Leca, E ;
Mentré, F ;
Guellec, CL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) :18-27
[3]   CYCLOSPORINE PHARMACOKINETICS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION IN PATIENTS WITH CROHNS-DISEASE [J].
BRYNSKOV, J ;
FREUND, L ;
CAMPANINI, MC ;
KAMPMANN, JP .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (11) :961-967
[4]   Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis [J].
Byrne, JL ;
Stainer, C ;
Hyde, H ;
Miflin, G ;
Haynes, AP ;
Bessell, EM ;
Russell, NH .
BONE MARROW TRANSPLANTATION, 1998, 22 (06) :541-545
[5]  
David-Neto E, 2000, J AM SOC NEPHROL, V11, P343, DOI 10.1681/ASN.V112343
[6]   Monitoring cyclosporine using blood drawn via a central venous catheter [J].
Donnelly, JP ;
Blijlevens, NMA ;
Schattenberg, AVMB .
BONE MARROW TRANSPLANTATION, 2003, 32 (10) :1037-1037
[8]  
HUNTER AE, 1992, BONE MARROW TRANSPL, V10, P431
[9]   Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients [J].
Irtan, S. ;
Saint-Marcoux, F. ;
Rousseau, A. ;
Zhang, D. ;
Leroy, V. ;
Marquet, P. ;
Jacqz-Aigrain, E. .
THERAPEUTIC DRUG MONITORING, 2007, 29 (01) :96-102
[10]  
Kagawa Y, 2003, BIOL PHARM BULL, V26, P1115